Trending...
- Ingleside Homes Receives $5,000 Award from the WSFS CARES Foundation for Health Equity Fund Program
- The OpenSSL Corporation Releases Its Annual Report 2025
VALFIX Medical is developing a trans-catheter solution for patients suffering from valvular heart disease and heart failure.
DOVER, Del. - DelTimes -- VALFIX Medical Inc. announces the issuance of a new patent by its Israeli subsidiary VALFIX Medical Ltd. The new Patent US 11,931,021 B2 is titled "Anchors and locks for percutaneous valve implants".
The granted patent outlines multiple locking mechanisms that secure an implant to its target location by applying gripping forces on a surgical suture that passes through the implant.
"It is exciting to receive the new patents as we continue to push the technology forward; our approach to valve repair remains unique and distinct in the market," stated Eli Bar, CEO and Founder of VALFIX Medical. "This patent granted confirms and protects our core technology and adds significant value to our stakeholders."
More on deltimes.com
VALFIX Medical technology is distinguished in its approach to offer valve repair method that truly replicate the surgical annuloplasty approach. Using specially designed anchors and locks VALFIX achieve unparalleled operational flexibility, anatomic precision, and implant stability.
This unique approach gives more options for interventional cardiologists to deliver the most effective therapy to this complex condition.
About VALFIX Medical:
VALFIX has developed an innovative transcatheter system to treat heart failure patients suffering from significant functional mitral valve regurgitation (FMR). VALFIX's unique and innovative transcatheter technology offers a viable alternative to open heart surgery.
To learn more about VALFIX Medical visit our website at www.valfixmed.com or
contact us directly at info@valfixmed.com
The granted patent outlines multiple locking mechanisms that secure an implant to its target location by applying gripping forces on a surgical suture that passes through the implant.
"It is exciting to receive the new patents as we continue to push the technology forward; our approach to valve repair remains unique and distinct in the market," stated Eli Bar, CEO and Founder of VALFIX Medical. "This patent granted confirms and protects our core technology and adds significant value to our stakeholders."
More on deltimes.com
- UK Financial Ltd Lists MayaFund (MFUND) ERC-20 Token on CATEX Exchange Ahead of Planned ERC-3643 Upgrade
- UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
- OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
- UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
- UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
VALFIX Medical technology is distinguished in its approach to offer valve repair method that truly replicate the surgical annuloplasty approach. Using specially designed anchors and locks VALFIX achieve unparalleled operational flexibility, anatomic precision, and implant stability.
This unique approach gives more options for interventional cardiologists to deliver the most effective therapy to this complex condition.
About VALFIX Medical:
VALFIX has developed an innovative transcatheter system to treat heart failure patients suffering from significant functional mitral valve regurgitation (FMR). VALFIX's unique and innovative transcatheter technology offers a viable alternative to open heart surgery.
To learn more about VALFIX Medical visit our website at www.valfixmed.com or
contact us directly at info@valfixmed.com
Source: Valfix medical Inc.
0 Comments